Anabolic-androgenic steroids: Historical background, physiology, typical use and side effects

Pharmacology, Doping and Sports: A Scientific Guide for Athletes, Coaches, Physicians, Scientists and Administrators

Volumn , Issue , 2008, Pages 23-35

  Clark, Richard V ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 61349121562     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9780203891049     Document Type: Chapter

References (71)

1. Wilson JD. Androgen abuse by athletes. Endocrine Reviews. 1988; 9: 181-99.
2. Bagatelle CJ, Bremner WJ. Androgens in men: uses and abuses. New England Journal of Medicine. 1996; 334: 707-14.
3. Matsumoto AM. Clinical use and abuse of androgens and antiandrogens. In: Becker KL, ed. Principles and practice of endocrinology and metabolism. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2001; 1181-200.
4. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Medicine. 2004; 34: 512-54.
5. Hoffman JR, Ratamess NA. Medical issues associated with anabolic steroid use: are they exaggerated? Journal of Sports Science and Medicine. 2006; 5: 182-93.
6. Forbes TR. Crowing hen: early observations on spontaneous sex reversal in birds. Yale Journal of Biology and Medicine. 1947; 19: 955-70.
7. Brown-Séquard C-E. Des effets produits chez l'homme par des injections souscutanées d'un liquide retiré des testicules frais de cobaye et de chien. Comptes rendus hebdomadaires des séances de la Société de Biologie (Paris). 1889; 1: 420-30.
8. Butenandt A. Über die chemische Untersuchung der Sexualhormons. Zeitschrift für angewandte Chemine. 1931; 44: 905-908.
9. Loewe S, Voss HE. Der Stand der Erfassung des männlichen Sexualhormons. Klinische Wochenschrift. 1930; 9: 481-7.
10. David K, Dingemanse E, Freud J, Laqueur E. Über krystallinisches männliches Hormon aus Hoden (Testosteron), wirksamer als aus Harn oder aus Cholesterin bereitetes Androsteron. Hoppe-Seylers Zeitschrift für physiologische Chemine. 1935; 233: 281.
11. Ruzicka L,Wettstein A. Synthetische Darstellung des Testishormons, Testosteron. Helvatica Chimica Acta. 1935; 18: 1264-75.
12. Kochakian CD, Murlin JR. The effect of male hormone on the protein and energy metabolism of castrate dogs. Journal of Nutrition. 1935; 10: 437.
13. Papanicolaou GN, Falk EA. General muscular hypertrophy induced by androgenic hormones. Science. 1938; 87: 238.
14. Knowlton K, Kenyon AT, Sandiford I, Loturin G, Fricker R. Comparative study of metabolic effects of estradiol benzoate and testosterone propionate in man. Journal of Clinical Endocrinology and Metabolism. 1942; 2: 671-84.
15. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. Journal of Clinical Endocrinology and Metabolism. 1980; 51: 1335-9.
16. Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertility and Sterility. 1982; 37: 425-30.
17. Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B, Faulkner S, Dudley RE, Swerdloff RS. Pharmacokineties of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites. Journal of Clinical Endocrinology and Metabolism. 2000; 85: 964-9.
18. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM,Weber T, Berman N; Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Journal of Clinical Endocrinology and Metabolism. 2000; 85: 2839-53.
19. Schubert M, Minnemann T, Hübler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. Journal of Clinical Endocrinology and Metabolism. 2004; 89: 5429-34.
20. Boje O. Bulletin of the Health Organization of the League of Nations. 1939; 8: 439-69.
21. Todd T. Anabolic steroids: the gremlins of sport. Journal of Sport History. 1987; 14: 87-107.
22. Yesalis CE, Courson SP, Wright J. History of anabolic steroid use in sport and exercise. In: Yesalis CE ed. Introduction to anabolic steroids in sport and exercise. 2nd ed. Champaign, IL: Human Kinetics, 2000; 51-71.
23. Forbes GB. The effect of anabolic steroids on lean body mass: the dose response curve. Metabolism. 1995; 34: 571-3.
24. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. New England Journal of Medicine. 1996; 335: 1-7.
25. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekow C, Dzekow J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW. Testosterone dose-response relationships in healthy young men. American Journal of Physiology. 2001; 281: E1172-E1181.
26. Herbst KL, Bhasin S. Testosterone action on skeletal muscle. Current Opinion on Clinical Nutrition and Metabolic Care. 2004; 7: 271-7.
27. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, Dzekov J, Magliano L, Storer TW. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. Journal of Clinical Endocrinology and Metabolism. 2005; 90: 678-88.
28. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, Lieberman SA, Tipton K, Wolfe RR, Urban RJ. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. American Journal of Physiolgy. 2002; 282: E601-E607.
29. Bhasin S, Taylor WE, Singh R, Artaza J, Sinha-Hikim I, Jasuja R, Choi H, Gonzalez-Cadavid NF. The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. Journal of Gerontological Biological Science and Medical Science. 2003; 58: M1103-M1110.
30. Chen Y, Zajac JD, MacLean HE. Androgen regulation of satellite cell function. Journal of Endocrinology. 2005; 186: 21-31.
31. Perry PJ, Lund BC, Deninger MJ, Kutscher EC, Schneider J. Anabolic steroid use in weightlifters and bodybuilders: an internet survey of drug utilization. Clinical Journal of Sport Medicine. 2005; 15: 326-30.
32. Haupt HA, Rovere GD. Anabolic steroids: a review of the literature. American Journal of Sports Medicine. 1984; 34: 69-84.
33. Elashoff JD, Jacknow AD, Shain SG, Braunstein GD. Effects of anabolicandrogenic steroids on muscular strength. Annals of Internal Medicine. 1991; 115: 387-93.
34. Giorgi A,Weatherby RP, Murphy PW. Muscular strength, body composition, and health responses to the use of testosterone enanthate: a double blind study. Journal of Science and Medicine in Sport. 1999; 2: 341-55.
35. Hartgens F, Van Marken Lichtenbelt WD, Ebbing S, Vollard N, Rietjens G, Kupers H. Body composition, anthropometry in bodybuilders: regional changes due to nandrolone decanoate administration. International Journal of Sports Medicine. 2001; 22: 235-41.
36. Zhou ZX, Wong CI, Sar M, Wilson EM. The androgen receptor: an overview. Recent Progress in Hormone Research. 1994; 49: 249-74.
37. Scheller A, Hughes E, Golden KL, Robins DM. Multiple receptor domains interact to permit or restrict androgen-specific gene interaction. Journal of Biological Chemistry. 1998; 273: 24216-22.
38. Heinlein CA, Chang C. Androgen receptor coregulators: an overview. Endocrine Reviews. 2002; 23: 175-200.
39. McEwan IJ. Molecular mechanisms of androgen receptor-mediated gene regulation: structure-function analysis of the AF-1 domain. Endocrine-Related Cancer. 2004; 11: 281-93.
40. Dobs AS. Is there a role for androgenic anabolic steroids in medical practice? Journal of the American Medical Association. 1999; 281: 1326-7.
41. Basaria S, Wahlstrom JT, Dobs AS. Anabolic-androgenic steroid therapy in the treatment of chronic diseases. Journal of Clinical Endocrinology and Metabolism. 2001; 86: 5108-17.
42. Orr R, Singh MF. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorder. Drugs. 2004; 64: 725-50.
43. Yesalis CE, Kennedy NJ, Kopstein AN, Bahrke MS. Anabolic-androgenic steroid use in the United States. Journal of the American Medical Association. 1993; 270: 1217-21.
44. National Institute on Drug Abuse. Anabolic steroids: a threat to mind and body. NIH Publication No. 96-3721, 1996.
45. Anderson RA, Wu F., Comparison between testosterone enanthate induced azoospermia and oligospermia in a male contraceptive study II. Journal of Clinical Endocrinology and Metabolism. 1996; 81: 896-901.
46. Torres-Calleja J, González-Unzaga M, DeCelis-Carrillo R, Calzada-Sánchez L, Pedrón N. Effect of androgenic anabolic steroids on sperm quality and serum hormones in adult male body builders. Life Science. 2001; 68: 1769-74.
47. Chang RJ. Polycystic ovary syndrome and hyperandrogenic states. In: Strauss JF, Barbieri RL, eds. Yen and Jaffe's Reproductive Endocrinology. 5th ed. Philadelphia: Elsevier Saunders, 2004; 597-632.
48. Ishak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic/androgenic steroids. Seminars in Liver Disease. 1987; 7: 230-6.
49. Soe KL, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver. 1992; 12: 73-9.
50. Socas L, Zumbado M, Pérez-Luzardo O, Ramos A, Pérez C, Hernández JR, Boada LD. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report on two cases and a review of the literature. British Journal of Sports Medicine. 2005; 39: e27.
51. Creagh TM, Rubin A, Evans DJ. Hepatic tumours induced by anabolic steroids in an athlete. Journal of Clinical Pathology. 1988; 41: 441-3.
52. Kosaka A, Hayakawa H, Kusagawa M, Takahashi H, Okamura K, Mizumoto R, Katsuta K. Hepatocellular carcinoma associated with anabolic steroid therapy. Journal of Gastroenterology. 1996; 31: 450-4.
53. Nieminen MS, Rämö MP, Viitasalo M, Heikkilä P, Karjalainen J, Mäntysaari M, Heikkilä J. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. European Heart Journal. 1996; 17: 1576-83.
54. Fineschi V, Baroldi G, Monciotti F, Paglicci Reattelli L, Turillazzi E. Anabolic steroid abuse and cardiac sudden death: a pathologic study. Archives of Pathology and Laboratory Medicine. 2001; 125: 253-5.
55. Dickerman RD, Stevens QE, Schneider SJ. Sudden cardiac death in a 20-year old bodybuilder using anabolic steroids. Cardiology. 1995; 86: 172-3.
56. Hausmann R, Hammer S, Betz P. Performance enhancing drugs (doping agents) and sudden death: a case report and review of the literature. International Journal of Legal Medicine. 1998; 111: 261-4.
57. Nottin S, Nguyen LD, Terbah M, Obert P. Cardiovascular effects of androgenic anabolic steroids in male bodybuilders determined by tissue Doppler imaging. American Journal of Cardiology. 2006; 97: 912-15.
58. Krieg A, Scharhag J, Albers T, Kindermann W, Urhausen A. Cardiac tissue Doppler imaging in sports medicine. Sports Medicine. 2007; 37: 15-30.
59. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. New England Journal of Medicine. 2000; 342: 1778-85.
60. Lenders JWM, Demacker PNM, Jansen JS, Hoitsma VL, van't Laar A, Thien T. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur bodybuilders. International Journal of Sports Medicine. 1988; 9: 22.
61. Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. Archives of Internal Medicine. 1991; 151: 1925-33.
62. Hurley BF, Seals DR, Hagberg JM, Goldberg AC, Ostrove SM, Holloszy JO, Wiest WG, Goldberg AP. High-density-lipoprotein cholesterol in bodybuilders v. powerlifters: negative effects of androgen use. Journal of the American Medical Association. 1984; 252: 507.
63. Parssinen M, Seppala T. Steroid use and long-term health risks in former athletes. Sports Medicine. 2002; 32: 83-94.
64. Bahrke MS, Wright JE, Strauss RH, Catlin DH. Psychological moods and subjectively perceived behavioral and somatic changes accompanying anabolicandrogenic steroid use. American Journal of Sports Medicine. 1992; 20: 717-24.
65. Pope Jr HG, Kouri EM, Hudson JI. Effects of supraphysiological doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Archives of General Psychiatry. 2000; 57: 133-40.
66. Pope, HG Jr, Katz DL. Affective and psychotic symptoms associated with anabolic steroid use. American Journal of Psychiatry. 1988; 145: 487.
67. Pope HJ, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. Archives of General Psychiatry. 1994; 51: 375-82.
68. Malone DA, Dimeff RJ, Lombardo JA. Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid users. Clinical Journal of Sport Medicine. 1995; 5: 25.
69. Thiblin I, Lindquist O, Rajs J. Causes and manner of death among users of anabolic androgenic steroids. Journal of Forensic Sciences. 2000; 45; 16-23.
70. Brower KF, Eliopulos GA, Blow FC, Catlin DH, Beresford TP. Evidence for physical and psychological dependence on anabolic-androgenic steroids in eight weightlifters. American Journal of Psychiatry. 1990; 147: 510-12.
71. Midgley SJ, Heather N, Davies JB. Dependence-producing potential of anabolicandrogenic steroids. Addiction Research and Theory. 1999; 7: 539-50.